GoLUCK personal page - To The Moon

GoLUCK

GoLUCK

No personal profile

7Follow

4Followers

0Topic

0Badge

2021-08-19

Good

Analysts upbeat on Tilray's U.S. prospects after MedMen deal

2021-08-17

Yes

Michael Burry of ‘Big Short’ Bets Against Cathie Wood’s ARKK

2021-07-28

Nice

Sorry, the original content has been removed

2021-07-21

Yes

Sorry, the original content has been removed

2021-07-18

Nice

3 Moves You'll Sorely Regret in a Stock Market Crash

2021-07-09

Nice

Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more

2021-07-05

Nice

Sorry, the original content has been removed

2021-07-05

Like and comment

Sorry, the original content has been removed

2021-07-04

Like pls

Sorry, the original content has been removed

2021-07-03

Wow

Sorry, the original content has been removed

2021-07-03

Like

Sorry, the original content has been removed

2021-06-23

Ok

Sorry, the original content has been removed

2021-06-23

Good

Sorry, the original content has been removed

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3582022156707091","uuid":"3582022156707091","gmtCreate":1619156641859,"gmtModify":1619162108196,"name":"GoLUCK","pinyin":"goluck","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":7,"tweetSize":13,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":831205881,"gmtCreate":1629328295443,"gmtModify":1676530001835,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831205881","repostId":"2160379017","repostType":4,"repost":{"id":"2160379017","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629300766,"share":"https://ttm.financial/m/news/2160379017?lang=&edition=fundamental","pubTime":"2021-08-18 23:32","market":"hk","language":"en","title":"Analysts upbeat on Tilray's U.S. prospects after MedMen deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2160379017","media":"Dow Jones","summary":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions ","content":"<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts upbeat on Tilray's U.S. prospects after MedMen deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts upbeat on Tilray's U.S. prospects after MedMen deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-18 23:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth</p>\n<p>Shares of <a href=\"https://laohu8.com/S/TLRY\">Tilray Inc.</a> rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.</p>\n<p>Gotham Green Partners, a backer of MedMen, is the seller on the deal.</p>\n<p>Tilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.</p>\n<p>Analyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.</p>\n<p>\"While an equity interest in a larger multi-state operator <a href=\"https://laohu8.com/S/MSO\">$(MSO)$</a> would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.</p>\n<p>He maintained his neutral rating on Tilray.</p>\n<p>Meanwhile, Oppenheimer &amp; Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.</p>\n<p>\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"</p>\n<p>Tilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the <a href=\"https://laohu8.com/S/THCX\">Cannabis ETF</a> (THCX) has gained 14.0% this year while the S&amp;P 500 index has advanced 18.3%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TLRY":"Tilray Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160379017","content_text":"Tilray stock rallies after Alliance Global's Grey said the deal, at a 'reasonable price,' positions company for stronger growth\nShares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.\nGotham Green Partners, a backer of MedMen, is the seller on the deal.\nTilray's stock (TLRY) shot up 4.7% in morning trading, paring earlier intraday gains of as much as 7.2%. Shares of MedMen (MMNFF), which trade over the counter, climbed 25.2%.\nAnalyst Aaron Grey of Alliance Global Partners said the transaction could open up an opportunity for Tilray to purchase the remaining portions of MedMen and position it for stronger growth if federal legalization of adult use cannabis takes place. MedMen's current footprint includes dispensaries in New York and California.\n\"While an equity interest in a larger multi-state operator $(MSO)$ would have provided TLRY with greater exposure to current U.S. cannabis markets, given the debt overhang on MMEN, TLRY was able to create its position at a more reasonable price,\" Grey wrote in a research note.\nHe maintained his neutral rating on Tilray.\nMeanwhile, Oppenheimer & Co.'s Rupesh Parikh reiterated a perform rating on Tilray and said the company recently disclosed a fiscal 2024 revenue target of $4 billion, including a \"meaningful\" contribution from the U.S. market.\n\"We continue to look favorably upon management's efforts to build out a global cannabis platform, but nearer-term we remain sidelined driven by a continued challenging industry backdrop,\" Parikh said.\"\nTilray's stock has lost 11.8% over the past three months but has run up 66.3% year to date. In comparison, the Cannabis ETF (THCX) has gained 14.0% this year while the S&P 500 index has advanced 18.3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839666050,"gmtCreate":1629157226470,"gmtModify":1676529946229,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839666050","repostId":"2160538227","repostType":4,"repost":{"id":"2160538227","kind":"news","pubTimestamp":1629156161,"share":"https://ttm.financial/m/news/2160538227?lang=&edition=fundamental","pubTime":"2021-08-17 07:22","market":"us","language":"en","title":"Michael Burry of ‘Big Short’ Bets Against Cathie Wood’s ARKK","url":"https://stock-news.laohu8.com/highlight/detail?id=2160538227","media":"Bloomberg","summary":"Filing shows Scion Asset Management has puts on ETF shares\nBurry is also betting heavily against Tes","content":"<ul>\n <li>Filing shows Scion Asset Management has puts on ETF shares</li>\n <li>Burry is also betting heavily against Tesla, a top Wood pick</li>\n</ul>\n<p>Michael Burry, the investor made famous by “The Big Short” movie, has taken aim at <a href=\"https://laohu8.com/S/AONE.U\">one</a> of Wall Street’s hottest stars.</p>\n<p>Burry’s Scion Asset Management owned bearish put contracts against 235,500 shares of <a href=\"https://laohu8.com/S/ARKK\">ARK Innovation ETF</a> (ticker ARKK) at the end of the second quarter, according to a regulatory filing Monday.</p>\n<p>The flagship exchange-traded fund of Cathie Wood and her firm Ark Investment Management has lured billions in the past year after her thematic tech-focused bets trounced the market in 2020. Wood and Ark have struggled to maintain their momentum this year, amid concerns about lofty valuations and accelerating inflation.</p>\n<p><img src=\"https://static.tigerbbs.com/0383f10786819e920837843c867d439a\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"></p>\n<p>Burry has been warning about unsustainable valuations in the market for months. In June, he cautioned that retail investors could be getting drawn into “the mother of all crashes” by investing in cryptocurrencies and meme stocks.</p>\n<p>A put contract gives Scion the right to sell shares in the ETF before a certain date and at a previously agreed price. Its value increases if shares drop below the threshold. The exact terms of the puts, and when they were purchased, are undisclosed.</p>\n<p>Burry has been indirectly betting against Wood for some time via a big position against&nbsp;Tesla Inc.-- one of Ark’s top picks and ARKK’s biggest holding.</p>\n<p>Monday’s filing, a quarterly requirement of hedge funds above a certain size, also shows that Burry increased his bearish wagers against the electric-vehicle maker, with puts on 1,075,500 Tesla shares. That’s up from 800,100 shares in the first quarter.</p>\n<p>ARKK dropped 2.6% as of closed in New York amid broad tech-stock declines. Tesla slumped 4.3% as the U.S. opened a formal investigation into the company’s Autopilot system.</p>\n<p>Burry rose to widespread fame when his successful bets against mortgage securities during the financial crisis were featured in “The Big Short,” the movie version of Michael Lewis’s best-selling book. Christian Bale portrayed the Scion founder and chief executive officer.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Michael Burry of ‘Big Short’ Bets Against Cathie Wood’s ARKK</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMichael Burry of ‘Big Short’ Bets Against Cathie Wood’s ARKK\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-17 07:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-08-16/-big-short-michael-burry-bets-against-flagship-cathie-wood-fund?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Filing shows Scion Asset Management has puts on ETF shares\nBurry is also betting heavily against Tesla, a top Wood pick\n\nMichael Burry, the investor made famous by “The Big Short” movie, has taken aim...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-08-16/-big-short-michael-burry-bets-against-flagship-cathie-wood-fund?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ARKK":"ARK Innovation ETF","TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2021-08-16/-big-short-michael-burry-bets-against-flagship-cathie-wood-fund?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160538227","content_text":"Filing shows Scion Asset Management has puts on ETF shares\nBurry is also betting heavily against Tesla, a top Wood pick\n\nMichael Burry, the investor made famous by “The Big Short” movie, has taken aim at one of Wall Street’s hottest stars.\nBurry’s Scion Asset Management owned bearish put contracts against 235,500 shares of ARK Innovation ETF (ticker ARKK) at the end of the second quarter, according to a regulatory filing Monday.\nThe flagship exchange-traded fund of Cathie Wood and her firm Ark Investment Management has lured billions in the past year after her thematic tech-focused bets trounced the market in 2020. Wood and Ark have struggled to maintain their momentum this year, amid concerns about lofty valuations and accelerating inflation.\n\nBurry has been warning about unsustainable valuations in the market for months. In June, he cautioned that retail investors could be getting drawn into “the mother of all crashes” by investing in cryptocurrencies and meme stocks.\nA put contract gives Scion the right to sell shares in the ETF before a certain date and at a previously agreed price. Its value increases if shares drop below the threshold. The exact terms of the puts, and when they were purchased, are undisclosed.\nBurry has been indirectly betting against Wood for some time via a big position against Tesla Inc.-- one of Ark’s top picks and ARKK’s biggest holding.\nMonday’s filing, a quarterly requirement of hedge funds above a certain size, also shows that Burry increased his bearish wagers against the electric-vehicle maker, with puts on 1,075,500 Tesla shares. That’s up from 800,100 shares in the first quarter.\nARKK dropped 2.6% as of closed in New York amid broad tech-stock declines. Tesla slumped 4.3% as the U.S. opened a formal investigation into the company’s Autopilot system.\nBurry rose to widespread fame when his successful bets against mortgage securities during the financial crisis were featured in “The Big Short,” the movie version of Michael Lewis’s best-selling book. Christian Bale portrayed the Scion founder and chief executive officer.","news_type":1},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803100979,"gmtCreate":1627426376491,"gmtModify":1703489536591,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803100979","repostId":"1170349743","repostType":4,"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176849810,"gmtCreate":1626877335530,"gmtModify":1703479814474,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176849810","repostId":"2153610465","repostType":4,"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173349271,"gmtCreate":1626621770793,"gmtModify":1703762413265,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173349271","repostId":"2152899486","repostType":4,"repost":{"id":"2152899486","kind":"highlight","pubTimestamp":1626530220,"share":"https://ttm.financial/m/news/2152899486?lang=&edition=fundamental","pubTime":"2021-07-17 21:57","market":"us","language":"en","title":"3 Moves You'll Sorely Regret in a Stock Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2152899486","media":"Motley Fool","summary":"A market downturn could happen when you least expect it. Don't make these mistakes when the next one hits.","content":"<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.</p>\n<p>But the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.</p>\n<h2>1. Selling when investment values plunge</h2>\n<p>When you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.</p>\n<p>If you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.</p>\n<p>When investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.</p>\n<h2>2. Pausing your retirement plan contributions</h2>\n<p>The point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.</p>\n<p>You may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.</p>\n<h2>3. Not adding discounted stocks to your portfolio</h2>\n<p>Many people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.</p>\n<p>During market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.</p>\n<p>For example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.</p>\n<p>Knowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Moves You'll Sorely Regret in a Stock Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Moves You'll Sorely Regret in a Stock Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152899486","content_text":"The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.\nBut the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.\n1. Selling when investment values plunge\nWhen you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.\nIf you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.\nWhen investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.\n2. Pausing your retirement plan contributions\nThe point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.\nYou may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.\n3. Not adding discounted stocks to your portfolio\nMany people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.\nDuring market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.\nFor example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.\nKnowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143526998,"gmtCreate":1625803424514,"gmtModify":1703748890188,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143526998","repostId":"1195657546","repostType":4,"repost":{"id":"1195657546","kind":"news","pubTimestamp":1625785913,"share":"https://ttm.financial/m/news/1195657546?lang=&edition=fundamental","pubTime":"2021-07-09 07:11","market":"hk","language":"en","title":"Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1195657546","media":"CNBC","summary":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strau","content":"<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 07:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACCD":"Accolade, Inc.","GM":"通用汽车","BGC":"BGC GROUP"},"source_url":"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1195657546","content_text":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter results. Levi reported adjusted earnings of 23 cents per share on revenue of $1.28 billion. Analysts expected earnings of 9 cents per share on revenue of $1.21 billion, according to Refinitiv.\nGeneral Motors— General Motors shares gained 1.3% after Wedbush initiated coverage of the stock with an outperform rating and $85 price target. That target implies an upside of more than 51% from Thursday's close. \"CEO Mary Barra along with other key executives has led the legacy auto company back to the top of the auto industry in the United States,\" Wedbush's Dan Ives said in a note.\nPriceSmart— Shares of PriceSmart rose 2.4% in thin trading on the back of the warehouse club operator’s third-quarter earnings report. PriceSmart posted earnings of 73 cents per share, compared with a FactSet estimate of 65 cents per share expectation.\nAccolade— Accolade shares added 1.2% in low-volume trading following after the company released its latest quarterly numbers. The health-care technology company reported revenue of of $59.5 million versus analysts’ $55.8 million estimate, according to FactSet. Accolade also posted a smaller-than-expected EBITDA loss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154334836,"gmtCreate":1625478175925,"gmtModify":1703742420400,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154334836","repostId":"1111176344","repostType":4,"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154335628,"gmtCreate":1625478130964,"gmtModify":1703742419254,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154335628","repostId":"1109703914","repostType":4,"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155980351,"gmtCreate":1625369086473,"gmtModify":1703740878799,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155980351","repostId":"1146176335","repostType":4,"isVote":1,"tweetType":1,"viewCount":577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152366771,"gmtCreate":1625271209393,"gmtModify":1703739627310,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152366771","repostId":"2148181808","repostType":4,"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152368056,"gmtCreate":1625271119175,"gmtModify":1703739623563,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152368056","repostId":"2148870441","repostType":4,"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123506627,"gmtCreate":1624427703869,"gmtModify":1703836375456,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123506627","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123501714,"gmtCreate":1624427620738,"gmtModify":1703836372839,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123501714","repostId":"1174011543","repostType":4,"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":154335628,"gmtCreate":1625478130964,"gmtModify":1703742419254,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/154335628","repostId":"1109703914","repostType":4,"repost":{"id":"1109703914","kind":"news","pubTimestamp":1625464355,"share":"https://ttm.financial/m/news/1109703914?lang=&edition=fundamental","pubTime":"2021-07-05 13:52","market":"us","language":"en","title":"Is the Stock Market Open or Closed on Independence Day?","url":"https://stock-news.laohu8.com/highlight/detail?id=1109703914","media":"Thestreet","summary":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.So will the major markets open or close for the holiday?The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.It's one of nine full-closing daysfor the stock market this year.For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading i","content":"<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.</p>\n<p>So will the major markets open or close for the holiday?</p>\n<p>The New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.</p>\n<p>It's&nbsp;one of nine full-closing daysfor the stock market this year.</p>\n<p>For instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.</p>\n<p>Normal stock-trading hours run 9:30 a.m. to 4 p.m. ET.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is the Stock Market Open or Closed on Independence Day?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs the Stock Market Open or Closed on Independence Day?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the...</p>\n\n<a href=\"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.thestreet.com/investing/independence-day-stock-markets-trading-hours","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109703914","content_text":"Independence Day in the U.S. is for many a picnic-and-beach day. But July 4 this year falls on a Sunday, which in the United States isn't a trading day.\nSo will the major markets open or close for the holiday?\nThe New York Stock Exchange and the Nasdaq will, in fact, be closed on Monday, July 5, to celebrate Independence Day.\nIt's one of nine full-closing daysfor the stock market this year.\nFor instance, the stock market will close for Thanksgiving on Thursday, Nov. 25. On Friday, Nov. 26, trading is scheduled for a bit more than a half-day, 9:30 a.m. to 1 p.m. ET.\nNormal stock-trading hours run 9:30 a.m. to 4 p.m. ET.","news_type":1},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143526998,"gmtCreate":1625803424514,"gmtModify":1703748890188,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/143526998","repostId":"1195657546","repostType":4,"repost":{"id":"1195657546","kind":"news","pubTimestamp":1625785913,"share":"https://ttm.financial/m/news/1195657546?lang=&edition=fundamental","pubTime":"2021-07-09 07:11","market":"hk","language":"en","title":"Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1195657546","media":"CNBC","summary":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strau","content":"<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks making the biggest moves after hours: Levi Strauss, General Motors, Accolade and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-09 07:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter ...</p>\n\n<a href=\"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACCD":"Accolade, Inc.","GM":"通用汽车","BGC":"BGC GROUP"},"source_url":"https://www.cnbc.com/2021/07/08/stocks-making-the-biggest-moves-after-hours-levi-strauss-gm-accolade.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1195657546","content_text":"Check out the companies making headlines after the bell Thursday:\nLevi Strauss— Shares of Levi Strauss added 3.2% after the retailer crushed Wall Street expectations in itsfiscal second-quarter results. Levi reported adjusted earnings of 23 cents per share on revenue of $1.28 billion. Analysts expected earnings of 9 cents per share on revenue of $1.21 billion, according to Refinitiv.\nGeneral Motors— General Motors shares gained 1.3% after Wedbush initiated coverage of the stock with an outperform rating and $85 price target. That target implies an upside of more than 51% from Thursday's close. \"CEO Mary Barra along with other key executives has led the legacy auto company back to the top of the auto industry in the United States,\" Wedbush's Dan Ives said in a note.\nPriceSmart— Shares of PriceSmart rose 2.4% in thin trading on the back of the warehouse club operator’s third-quarter earnings report. PriceSmart posted earnings of 73 cents per share, compared with a FactSet estimate of 65 cents per share expectation.\nAccolade— Accolade shares added 1.2% in low-volume trading following after the company released its latest quarterly numbers. The health-care technology company reported revenue of of $59.5 million versus analysts’ $55.8 million estimate, according to FactSet. Accolade also posted a smaller-than-expected EBITDA loss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831205881,"gmtCreate":1629328295443,"gmtModify":1676530001835,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/831205881","repostId":"2160379017","repostType":4,"isVote":1,"tweetType":1,"viewCount":518,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173349271,"gmtCreate":1626621770793,"gmtModify":1703762413265,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/173349271","repostId":"2152899486","repostType":4,"repost":{"id":"2152899486","kind":"highlight","pubTimestamp":1626530220,"share":"https://ttm.financial/m/news/2152899486?lang=&edition=fundamental","pubTime":"2021-07-17 21:57","market":"us","language":"en","title":"3 Moves You'll Sorely Regret in a Stock Market Crash","url":"https://stock-news.laohu8.com/highlight/detail?id=2152899486","media":"Motley Fool","summary":"A market downturn could happen when you least expect it. Don't make these mistakes when the next one hits.","content":"<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.</p>\n<p>But the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.</p>\n<h2>1. Selling when investment values plunge</h2>\n<p>When you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.</p>\n<p>If you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.</p>\n<p>When investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.</p>\n<h2>2. Pausing your retirement plan contributions</h2>\n<p>The point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.</p>\n<p>You may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.</p>\n<h2>3. Not adding discounted stocks to your portfolio</h2>\n<p>Many people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.</p>\n<p>During market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.</p>\n<p>For example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.</p>\n<p>Knowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Moves You'll Sorely Regret in a Stock Market Crash</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Moves You'll Sorely Regret in a Stock Market Crash\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-17 21:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/17/3-moves-youll-sorely-regret-in-a-stock-market-cras/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152899486","content_text":"The scary thing about stock market crashes is that they can happen when you least expect them to. And while stock market crashes are normal in that they actually occur somewhat frequently, they can be terrifying for investors who aren't used to them.\nBut the decisions you make during a market crash will dictate whether you survive it unscathed, or whether you end up taking serious losses you don't recover from for years. With that in mind, here are three moves you might seriously regret during a stock market downturn.\n1. Selling when investment values plunge\nWhen you buy stocks, you lock in those investments at a certain price. That price can then rise or fall on an ongoing basis.\nIf you don't sell your stocks while their value is up, you won't make money. Similarly, if you don't sell your stocks when their values declines, you won't suffer losses. It's the latter you really need to keep in mind during a stock market crash.\nWhen investment values start to fall, it can very tempting to cash out investments in an effort to minimize the blow. But the stock market has a long history of recovering from crashes, so if you leave your portfolio alone, you'll give your stock values a chance to come back up rather than guarantee yourself losses that could've been easily avoided.\n2. Pausing your retirement plan contributions\nThe point of putting money into a 401(k) or IRA isn't to just let it sit there in cash. Rather, you're supposed to invest it so it grows into a large sum over time.\nYou may be inclined to stop funding your retirement savings during periods when the stock market is doing poorly. But that's a mistake. The money that goes into your retirement plan gets tax-advantaged treatment, whether immediately or in the future, so it pays to keep pumping cash into your account even when the stock market isn't at its strongest.\n3. Not adding discounted stocks to your portfolio\nMany people assume that buying stocks during a market crash is a bad idea. But actually, the opposite is true.\nDuring market downturns, stock values tend to fall across the board. But that doesn't necessarily mean that the companies you're interested in are actually worth less money than they were the month prior. It just means that temporarily, their share prices are down. That gives you a prime opportunity to buy quality stocks when they're less expensive.\nFor example, if you're interested in a given company whose share prices has been hovering around $50, during a market crash, it might fall to $40. Does that mean that from now on, shares will only be worth 40? Not at all. But if you scoop them up at $40 apiece, you'll set yourself up to profit big time when their values creeps back up to $50 or beyond.\nKnowing how to navigate a stock market crash could prevent you from making poor decisions that hurt you financially. Avoid the above mistakes the next time the market takes a turn for the worse -- you'll be much better off for it in the long run.","news_type":1},"isVote":1,"tweetType":1,"viewCount":564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":155980351,"gmtCreate":1625369086473,"gmtModify":1703740878799,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/155980351","repostId":"1146176335","repostType":4,"repost":{"id":"1146176335","kind":"news","pubTimestamp":1625277627,"share":"https://ttm.financial/m/news/1146176335?lang=&edition=fundamental","pubTime":"2021-07-03 10:00","market":"us","language":"en","title":"Can Alibaba Turn Around Its Woes in the Second Half of 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=1146176335","media":"The Street","summary":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?Alibaba  -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.Howeve","content":"<blockquote>\n Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n</blockquote>\n<p>Alibaba&nbsp;(<b>BABA</b>) -Get Report&nbsp;has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.</p>\n<p>Regulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.</p>\n<p>Investors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.</p>\n<p>However, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.</p>\n<p>All of this comes as the S&amp;P 500 and Nasdaq continue to grind outnew all-time highs.</p>\n<p>It also comes as FAANG stocks continue to trade incredibly well. Alphabet&nbsp;(<b>GOOGL</b>) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix&nbsp;(<b>NFLX</b>) -Get Report&nbsp;is the worst, with a 2.3% drop.</p>\n<p>Alibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.</p>\n<p>Can it turn around its woes in the second half and start rallying higher?</p>\n<p><img src=\"https://static.tigerbbs.com/9975f383919ff8cfc34fca49a32d8e8f\" tg-width=\"700\" tg-height=\"494\"></p>\n<p>Call me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.</p>\n<p>The overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon&nbsp;(<b>AMZN</b>) -Get Report.Eventually, it will perform better&nbsp;- it’s a question of “when” and not “if.”</p>\n<p>Shares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.</p>\n<p>Specifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.</p>\n<p>Let’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.</p>\n<p>However, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.</p>\n<p>A push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.</p>\n<p>Keep the risk in mind but this could be a solid second-half rebound play.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Alibaba Turn Around Its Woes in the Second Half of 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Alibaba Turn Around Its Woes in the Second Half of 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-03 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were ...</p>\n\n<a href=\"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09618":"京东集团-SW","BABA":"阿里巴巴"},"source_url":"https://www.thestreet.com/investing/alibaba-baba-stock-second-half-2021-trading?puc=yahoo&cm_ven=YAHOO","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146176335","content_text":"Alibaba has been a sore laggard compared with its large- and mega-cap peers. Can that change in the second half of 2021?\n\nAlibaba (BABA) -Get Report has been a total dog so far this year. Shares were trading well into the fourth quarter of 2020 but then a string of issues pummeled the stock.\nRegulators disrupted Ant's initial public offering, then dug deeper on Alibaba and dialed up the heat.\nInvestors don’t like regulatory issues as it is but particularly when we’re dealing with Chinese regulators.\nHowever, in April, Alibaba paid a smaller-than-expectedbut still record fine, hoping to puts its regulatory issues behind it. Still, the stock hasn’t responded the way bulls were hoping.\nAll of this comes as the S&P 500 and Nasdaq continue to grind outnew all-time highs.\nIt also comes as FAANG stocks continue to trade incredibly well. Alphabet (GOOGL) -Get Reportis the top performerwith a near-40% gain in the first half of the year, while Netflix (NFLX) -Get Report is the worst, with a 2.3% drop.\nAlibaba has a similar first-half performance, down 2.6%. However, it’s doing far worse from the highs, down more than 30%.\nCan it turn around its woes in the second half and start rallying higher?\n\nCall me a hopeless optimist, but I feel that Alibaba can have a solid second-half performance.\nThe overall market has done too well and so has large-cap tech. The fundamentals of the business are intact and growth is strong. It’s like Amazon (AMZN) -Get Report.Eventually, it will perform better - it’s a question of “when” and not “if.”\nShares continue to hold the $210 to $212 area and have recently cleared downtrend resistance (blue line). That said, there’s plenty of overhead hurdles.\nSpecifically, Alibaba stock is struggling with the 21-week moving average, as well as the 21-month and 10-month moving averages.\nLet’s be clear: There are not a lot of bullish technical components here. If Alibaba stock could hold the 10-week moving average on this week’s dip, I’d feel better about it.\nHowever, as long as it can hold up over the $210 level and really, the 200-week moving average, I feel okay about Alibaba going into the next six months.\nA push over $235 - thus putting it over all of the moving average hurdles mentioned above - could open up a run to $250, then $263. Above $275 and $300 is in play.\nKeep the risk in mind but this could be a solid second-half rebound play.","news_type":1},"isVote":1,"tweetType":1,"viewCount":577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152368056,"gmtCreate":1625271119175,"gmtModify":1703739623563,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152368056","repostId":"2148870441","repostType":4,"repost":{"id":"2148870441","kind":"highlight","pubTimestamp":1625239935,"share":"https://ttm.financial/m/news/2148870441?lang=&edition=fundamental","pubTime":"2021-07-02 23:32","market":"us","language":"en","title":"1 Big Reason to Buy Snowflake Stock Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2148870441","media":"Motley Fool","summary":"Snowflake stock is priced at the moment for very long-term investors only.","content":"<p>Even after almost a year since its IPO and down some 30% in price from where it was in initial public trading, <b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a> </b>(NYSE:SNOW) remains <a href=\"https://laohu8.com/S/AONE\">one</a> of the most notoriously \"expensive\" stocks out there. Shareholders are pricing in years' worth of torrid growth. Snowflake recently added fuel to that fire, though, issuing some very specific and very ambitious revenue goals targeted for completion nearly a decade from now.</p>\n<p>There are pitfalls with projecting financial results too far into the future. Business is an unpredictable game, and we live in a fast-changing world. Nevertheless, cloud computing is an unstoppable force, and Snowflake is in pole position in a very important area of that expanding market. Don't go off and buy this stock hand over fist, but if you are willing to give this <a href=\"https://laohu8.com/S/AONE.U\">one</a> a shot for a decade or more, there are reasons you might want to add it to your watchlist at the very least.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F632438%2Fdata-center.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"393\"><span>Image source: Getty Images.</span></p>\n<h2>When even stellar financial results don't really matter</h2>\n<p>Snowflake continues to deliver the goods since becoming a public concern. Revenue in Q1 2021 notched a 110% year-over-year increase to $229 million, and full-year 2021 guidance is calling for a first-ever $1 billion in annual sales -- implying growth of no less than 84% from 2020. The company also anticipates reaching break-even on an adjusted free cash flow basis. Not bad at all, Snowflake.</p>\n<p>However, the rub for many investors is that the stock still trades for over 65 times full-year 2021 expected sales to enterprise value (market cap minus cash and equivalents). It's an incredible valuation, pricing in not just the expectation that the cloud computing industry will grow by double-digit percentages for the foreseeable future, but also that Snowflake's leading \"Data Cloud\" service will remain a leader among its peers in data management.</p>\n<p>Companies projecting growth too far into the future (and investors paying up for that growth and accepting a steep premium price tag) can be problematic. Business trends can change quickly, and competitors both old and new can present headaches for a company's growth trajectory. It thus comes as little surprise that Snowflake stock has been stuck in a volatile downward-trending line since its IPO last autumn.</p>\n<p>Snowflake is happy to oblige those who have been willing to take on the risk of buying, though. While most companies shy away from providing any sort of specific guidance beyond a year, not Snowflake. During its 2021 investor day presentation, it provided a product revenue goal all the way out to fiscal year 2029: $10 billion. If 2021 expectations for just over $1 billion transpire, the 2029 projection represents an average annual compound growth rate of over 33%, and it values the stock at under seven times 2029 sales.</p>\n<h2>A pie-in-the-sky goal?</h2>\n<p>Before you balk at such an ambitious very long-term projection, consider a few items. Cloud computing is a massive secular growth trend. Spending on cloud computing could reach $1 <i>trillion per year </i>by the end of this decade. And within the current greater cloud industry -- pegged at just over $330 billion in global spend this year by tech researcher <b>Gartner</b> -- application and infrastructure services (the corner of the cloud sandbox Snowflake is making snow angels in) are over one-third of the total spend.</p>\n<p>Put another way, this is a massive space, and Snowflake is indeed just one flake among a blizzard of cloud services out there.</p>\n<p>Cast in that light, $10 billion in sales in nearly a decade, in an industry that could soak up over a trillion dollars per year, suddenly doesn't seem so ambitious. In fact, Snowflake's goal could be downright achievable. And don't forget this company has nearly $4 billion in cash, another $1.2 billion in long-term investments, and no debt. That's quite the war chest it could deploy on new products or acquisitions -- making its long-term plan that much more easily within reach.</p>\n<p>The most pressing question, of course, is this: Is the stock a buy? If you need the money within a couple of years, or don't have the patience or temperament to wait out what is sure to be a wild ride over the next eight to 10 years, probably not. But if you're ultra-long on the cloud industry, you're still saving money and can plan to buy more Snowflake stock over time if the bull thesis plays out, maybe paying less than seven times sales projected into 2029 isn't such a bad idea.</p>\n<p>At the very least, put this stock on your watchlist and do some more due diligence to flesh out whether or not you believe management's messaging. I, for one, am warming up to the idea of making an initial investment.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>1 Big Reason to Buy Snowflake Stock Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n1 Big Reason to Buy Snowflake Stock Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/02/1-big-reason-to-buy-snowflake-stock-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Even after almost a year since its IPO and down some 30% in price from where it was in initial public trading, Snowflake (NYSE:SNOW) remains one of the most notoriously \"expensive\" stocks out there. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/02/1-big-reason-to-buy-snowflake-stock-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/07/02/1-big-reason-to-buy-snowflake-stock-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148870441","content_text":"Even after almost a year since its IPO and down some 30% in price from where it was in initial public trading, Snowflake (NYSE:SNOW) remains one of the most notoriously \"expensive\" stocks out there. Shareholders are pricing in years' worth of torrid growth. Snowflake recently added fuel to that fire, though, issuing some very specific and very ambitious revenue goals targeted for completion nearly a decade from now.\nThere are pitfalls with projecting financial results too far into the future. Business is an unpredictable game, and we live in a fast-changing world. Nevertheless, cloud computing is an unstoppable force, and Snowflake is in pole position in a very important area of that expanding market. Don't go off and buy this stock hand over fist, but if you are willing to give this one a shot for a decade or more, there are reasons you might want to add it to your watchlist at the very least.\nImage source: Getty Images.\nWhen even stellar financial results don't really matter\nSnowflake continues to deliver the goods since becoming a public concern. Revenue in Q1 2021 notched a 110% year-over-year increase to $229 million, and full-year 2021 guidance is calling for a first-ever $1 billion in annual sales -- implying growth of no less than 84% from 2020. The company also anticipates reaching break-even on an adjusted free cash flow basis. Not bad at all, Snowflake.\nHowever, the rub for many investors is that the stock still trades for over 65 times full-year 2021 expected sales to enterprise value (market cap minus cash and equivalents). It's an incredible valuation, pricing in not just the expectation that the cloud computing industry will grow by double-digit percentages for the foreseeable future, but also that Snowflake's leading \"Data Cloud\" service will remain a leader among its peers in data management.\nCompanies projecting growth too far into the future (and investors paying up for that growth and accepting a steep premium price tag) can be problematic. Business trends can change quickly, and competitors both old and new can present headaches for a company's growth trajectory. It thus comes as little surprise that Snowflake stock has been stuck in a volatile downward-trending line since its IPO last autumn.\nSnowflake is happy to oblige those who have been willing to take on the risk of buying, though. While most companies shy away from providing any sort of specific guidance beyond a year, not Snowflake. During its 2021 investor day presentation, it provided a product revenue goal all the way out to fiscal year 2029: $10 billion. If 2021 expectations for just over $1 billion transpire, the 2029 projection represents an average annual compound growth rate of over 33%, and it values the stock at under seven times 2029 sales.\nA pie-in-the-sky goal?\nBefore you balk at such an ambitious very long-term projection, consider a few items. Cloud computing is a massive secular growth trend. Spending on cloud computing could reach $1 trillion per year by the end of this decade. And within the current greater cloud industry -- pegged at just over $330 billion in global spend this year by tech researcher Gartner -- application and infrastructure services (the corner of the cloud sandbox Snowflake is making snow angels in) are over one-third of the total spend.\nPut another way, this is a massive space, and Snowflake is indeed just one flake among a blizzard of cloud services out there.\nCast in that light, $10 billion in sales in nearly a decade, in an industry that could soak up over a trillion dollars per year, suddenly doesn't seem so ambitious. In fact, Snowflake's goal could be downright achievable. And don't forget this company has nearly $4 billion in cash, another $1.2 billion in long-term investments, and no debt. That's quite the war chest it could deploy on new products or acquisitions -- making its long-term plan that much more easily within reach.\nThe most pressing question, of course, is this: Is the stock a buy? If you need the money within a couple of years, or don't have the patience or temperament to wait out what is sure to be a wild ride over the next eight to 10 years, probably not. But if you're ultra-long on the cloud industry, you're still saving money and can plan to buy more Snowflake stock over time if the bull thesis plays out, maybe paying less than seven times sales projected into 2029 isn't such a bad idea.\nAt the very least, put this stock on your watchlist and do some more due diligence to flesh out whether or not you believe management's messaging. I, for one, am warming up to the idea of making an initial investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":156,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839666050,"gmtCreate":1629157226470,"gmtModify":1676529946229,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839666050","repostId":"2160538227","repostType":4,"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803100979,"gmtCreate":1627426376491,"gmtModify":1703489536591,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/803100979","repostId":"1170349743","repostType":4,"repost":{"id":"1170349743","kind":"news","pubTimestamp":1627399823,"share":"https://ttm.financial/m/news/1170349743?lang=&edition=fundamental","pubTime":"2021-07-27 23:30","market":"us","language":"en","title":"Moderna Says Foreign Manufacturing Partners Facing Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=1170349743","media":"Bloomberg","summary":"Problem has been resolved, but it has slowed release of shots\nModerna says shipping shots as it make","content":"<ul>\n <li>Problem has been resolved, but it has slowed release of shots</li>\n <li>Moderna says shipping shots as it makes them, no extra on hand</li>\n</ul>\n<p>Moderna Inc.&nbsp;said its Covid-19 vaccine manufacturing partners outside the U.S. are “facing delays” due to laboratory testing issues that occurred in recent days.</p>\n<p>While the problem has been resolved, it has slowed release of Moderna’s vaccine to markets outside the U.S., a company spokeswoman said in an email.</p>\n<p>The problem will cause short-term adjustments to vaccine delivery outside the U.S., she said in the email.</p>\n<p>Moderna is currently shipping vaccine as it makes it, which means it has no extra stock in storage to smooth over these types of temporary supply interruptions, spokeswoman Colleen Hussey said in an email.</p>\n<p>Shares of Moderna fell as much as 4.5% in New York trading on Tuesday.</p>\n<p>Earlier, South Korea’s prime minister&nbsp;said at a meeting&nbsp;that Moderna had notified the country that an adjustment in the vaccine supply schedule is “inevitable” due to a “production setback issue.”</p>\n<p>“We will remain in close contact with governments, recognizing the importance of delivery planning for vaccination roll-out,” Moderna said in the statement. “Moderna and its manufacturing partners are working together to minimize this shortfall across all impacted nations.”</p>\n<p>Moderna didn’t specify where the problems occurred. Its partners outside the U.S. include&nbsp;Lonza Group AG, which makes the vaccine substance, and&nbsp;Laboratorios Farmaceuticos Rovi SA&nbsp;in Spain, which fills vaccine vials.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Says Foreign Manufacturing Partners Facing Delays</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Says Foreign Manufacturing Partners Facing Delays\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-07-27/moderna-says-foreign-manufacturing-partners-are-facing-delays?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Problem has been resolved, but it has slowed release of shots\nModerna says shipping shots as it makes them, no extra on hand\n\nModerna Inc. said its Covid-19 vaccine manufacturing partners outside the ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-07-27/moderna-says-foreign-manufacturing-partners-are-facing-delays?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.bloomberg.com/news/articles/2021-07-27/moderna-says-foreign-manufacturing-partners-are-facing-delays?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170349743","content_text":"Problem has been resolved, but it has slowed release of shots\nModerna says shipping shots as it makes them, no extra on hand\n\nModerna Inc. said its Covid-19 vaccine manufacturing partners outside the U.S. are “facing delays” due to laboratory testing issues that occurred in recent days.\nWhile the problem has been resolved, it has slowed release of Moderna’s vaccine to markets outside the U.S., a company spokeswoman said in an email.\nThe problem will cause short-term adjustments to vaccine delivery outside the U.S., she said in the email.\nModerna is currently shipping vaccine as it makes it, which means it has no extra stock in storage to smooth over these types of temporary supply interruptions, spokeswoman Colleen Hussey said in an email.\nShares of Moderna fell as much as 4.5% in New York trading on Tuesday.\nEarlier, South Korea’s prime minister said at a meeting that Moderna had notified the country that an adjustment in the vaccine supply schedule is “inevitable” due to a “production setback issue.”\n“We will remain in close contact with governments, recognizing the importance of delivery planning for vaccination roll-out,” Moderna said in the statement. “Moderna and its manufacturing partners are working together to minimize this shortfall across all impacted nations.”\nModerna didn’t specify where the problems occurred. Its partners outside the U.S. include Lonza Group AG, which makes the vaccine substance, and Laboratorios Farmaceuticos Rovi SA in Spain, which fills vaccine vials.","news_type":1},"isVote":1,"tweetType":1,"viewCount":438,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176849810,"gmtCreate":1626877335530,"gmtModify":1703479814474,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/176849810","repostId":"2153610465","repostType":4,"repost":{"id":"2153610465","kind":"highlight","pubTimestamp":1626867300,"share":"https://ttm.financial/m/news/2153610465?lang=&edition=fundamental","pubTime":"2021-07-21 19:35","market":"us","language":"en","title":"Will Pfizer Be Worth More Than Tesla by 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2153610465","media":"Motley Fool","summary":"Tesla sped past Pfizer last year.","content":"<p>Only about a year ago, we may have asked the opposite question: Will electric-car maker <b>Tesla</b>'s market cap surpass that of pharmaceutical giant <b>Pfizer</b> (NYSE:PFE) <a href=\"https://laohu8.com/S/AONE.U\">one</a> day? Pfizer's market value totaled about $200 billion. And at its lowest point last spring, Tesla's market cap dipped to $84 billion.</p>\n<p>A lot has happened since then. Pfizer became the first to commercialize a coronavirus vaccine -- and that vaccine is generating billions of dollars in revenue. And Tesla delivered of a half a million cars in 2020. So far, investors have rewarded Tesla more than they've rewarded Pfizer. Tesla's market cap soared 794% last year -- well surpassing that of Pfizer. Now the question is whether the pharmaceutical company can transform strong revenue into share gains -- and top Tesla's market value.</p>\n<p><img src=\"https://static.tigerbbs.com/ffc43a399cfd6d79ff6a5b97fb309193\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Pfizer versus Tesla</h3>\n<p>First, let's look at Pfizer's market value growth so far compared with that of Tesla. Pfizer's value has remained in the $200 billion range for the past 20 years. Historically, Tesla's value has been much lower. But the company showed its ability to win over investors -- and quickly -- last year. Market value skyrocketed -- and now totals about $622 billion.</p>\n<p><img src=\"https://static.tigerbbs.com/6059efacae7e02376521e0412da281c5\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>PFE Market Cap data by YCharts</p>\n<p>If Tesla continues growing -- even at a slower pace -- it will be tough to beat. But let's make things simple and use today's market cap figure. So the idea is: Can Pfizer reach a market cap of about $622 billion over the coming four years?</p>\n<p>The fundamentals paint a bright picture. Pfizer is the coronavirus vaccine leader. It's vaccinated the biggest share of the U.S. population. And in the European Union, the company recently won a contract to supply as many as 1.8 billion vaccine doses through 2023. That's after an earlier contract for 600 million doses to be delivered this year. Pfizer expects the vaccine to generate $26 billion in revenue in 2021. Of course, it splits profits with partner <b>BioNTech</b>. But this still represents a blockbuster level product for Pfizer. In fact, the company said the vaccine will account for 36% of its revenue this year.</p>\n<p>Contracts -- such as the one with Europe -- indicate the company can count on vaccine revenue beyond this year. Experts also have confirmed this, saying the coronavirus is here to stay. And Pfizer's CEO has said we probably should expect vaccinations on an annual basis.</p>\n<h3>More good news</h3>\n<p>Here's more good news for Pfizer: It doesn't rely only on the coronavirus vaccine for revenue. The big pharma company has several other growing products such as heart failure drug Vyndaqel and anticoagulant Eliquis. Their sales rose 88% and 25%, respectively, in the first quarter.</p>\n<p>All of this is contributing to higher revenue on the horizon. The midpoint of Pfizer's full-year forecast represents a 71% increase in revenue year over year. The company predicts $70.5 billion to $72.5 billion in revenue this year.</p>\n<p>How has Pfizer's vaccine leadership -- and growth in other products -- translated into market cap and share price growth so far? Over the past year, both are up about 17%.</p>\n<p><img src=\"https://static.tigerbbs.com/c5b054d9789de4aa95d2320e23811cfc\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>PFE Market Cap data by YCharts</p>\n<p>That's not a huge move. Especially considering the world's focus on coronavirus vaccines. Biotech companies in the vaccine race saw much bigger gains. For example, <b>Moderna</b>'s share price and market cap have risen more than 200% in the same time period.</p>\n<p>Pfizer's market cap would have to increase 178% to reach Tesla's current market cap. Considering the growth in valuation we've seen so far, I'm not convinced Pfizer will surpass Tesla in the next few years. Past performance shows that even over the past 10 years, Pfizer's market value only climbed 50%.</p>\n<h3>What does this mean for investors?</h3>\n<p>Pfizer may not see its market value multiply at the speed of light. But the stock still represents a sure and steady play for long-term investors. Overall revenue is on the rise thanks to a broad array of commercialized products. And the coronavirus vaccine seems to be in the early days of its revenue story. It's important to keep in mind that future boosters and use in younger age groups should add to orders and sales. Of course, Pfizer probably won't leave Tesla in the dust. But this pharma stock still is likely to drive the value of your investment higher over time.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Pfizer Be Worth More Than Tesla by 2025?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Pfizer Be Worth More Than Tesla by 2025?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 19:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/21/will-pfizer-be-worth-more-than-tesla-by-2025/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Only about a year ago, we may have asked the opposite question: Will electric-car maker Tesla's market cap surpass that of pharmaceutical giant Pfizer (NYSE:PFE) one day? Pfizer's market value totaled...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/21/will-pfizer-be-worth-more-than-tesla-by-2025/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/07/21/will-pfizer-be-worth-more-than-tesla-by-2025/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153610465","content_text":"Only about a year ago, we may have asked the opposite question: Will electric-car maker Tesla's market cap surpass that of pharmaceutical giant Pfizer (NYSE:PFE) one day? Pfizer's market value totaled about $200 billion. And at its lowest point last spring, Tesla's market cap dipped to $84 billion.\nA lot has happened since then. Pfizer became the first to commercialize a coronavirus vaccine -- and that vaccine is generating billions of dollars in revenue. And Tesla delivered of a half a million cars in 2020. So far, investors have rewarded Tesla more than they've rewarded Pfizer. Tesla's market cap soared 794% last year -- well surpassing that of Pfizer. Now the question is whether the pharmaceutical company can transform strong revenue into share gains -- and top Tesla's market value.\n\nImage source: Getty Images.\nPfizer versus Tesla\nFirst, let's look at Pfizer's market value growth so far compared with that of Tesla. Pfizer's value has remained in the $200 billion range for the past 20 years. Historically, Tesla's value has been much lower. But the company showed its ability to win over investors -- and quickly -- last year. Market value skyrocketed -- and now totals about $622 billion.\n\nPFE Market Cap data by YCharts\nIf Tesla continues growing -- even at a slower pace -- it will be tough to beat. But let's make things simple and use today's market cap figure. So the idea is: Can Pfizer reach a market cap of about $622 billion over the coming four years?\nThe fundamentals paint a bright picture. Pfizer is the coronavirus vaccine leader. It's vaccinated the biggest share of the U.S. population. And in the European Union, the company recently won a contract to supply as many as 1.8 billion vaccine doses through 2023. That's after an earlier contract for 600 million doses to be delivered this year. Pfizer expects the vaccine to generate $26 billion in revenue in 2021. Of course, it splits profits with partner BioNTech. But this still represents a blockbuster level product for Pfizer. In fact, the company said the vaccine will account for 36% of its revenue this year.\nContracts -- such as the one with Europe -- indicate the company can count on vaccine revenue beyond this year. Experts also have confirmed this, saying the coronavirus is here to stay. And Pfizer's CEO has said we probably should expect vaccinations on an annual basis.\nMore good news\nHere's more good news for Pfizer: It doesn't rely only on the coronavirus vaccine for revenue. The big pharma company has several other growing products such as heart failure drug Vyndaqel and anticoagulant Eliquis. Their sales rose 88% and 25%, respectively, in the first quarter.\nAll of this is contributing to higher revenue on the horizon. The midpoint of Pfizer's full-year forecast represents a 71% increase in revenue year over year. The company predicts $70.5 billion to $72.5 billion in revenue this year.\nHow has Pfizer's vaccine leadership -- and growth in other products -- translated into market cap and share price growth so far? Over the past year, both are up about 17%.\n\nPFE Market Cap data by YCharts\nThat's not a huge move. Especially considering the world's focus on coronavirus vaccines. Biotech companies in the vaccine race saw much bigger gains. For example, Moderna's share price and market cap have risen more than 200% in the same time period.\nPfizer's market cap would have to increase 178% to reach Tesla's current market cap. Considering the growth in valuation we've seen so far, I'm not convinced Pfizer will surpass Tesla in the next few years. Past performance shows that even over the past 10 years, Pfizer's market value only climbed 50%.\nWhat does this mean for investors?\nPfizer may not see its market value multiply at the speed of light. But the stock still represents a sure and steady play for long-term investors. Overall revenue is on the rise thanks to a broad array of commercialized products. And the coronavirus vaccine seems to be in the early days of its revenue story. It's important to keep in mind that future boosters and use in younger age groups should add to orders and sales. Of course, Pfizer probably won't leave Tesla in the dust. But this pharma stock still is likely to drive the value of your investment higher over time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":154334836,"gmtCreate":1625478175925,"gmtModify":1703742420400,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/154334836","repostId":"1111176344","repostType":4,"repost":{"id":"1111176344","kind":"news","pubTimestamp":1625463785,"share":"https://ttm.financial/m/news/1111176344?lang=&edition=fundamental","pubTime":"2021-07-05 13:43","market":"us","language":"en","title":"Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1111176344","media":"Benzinga","summary":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq ","content":"<p>Biotech stocks underperformed the broader market in the first half of 2021, with the&nbsp;<b>iShares Nasdaq Biotechnology ETF</b>&nbsp;advancing about 8% year-to-date&nbsp;compared to the roughly 14% gain for the S&amp;P 500 Index.</p>\n<p>In comparison, the IBB was up 13.6% in the first half of 2020. The strength in the space in the last year was primarily due to risk aversion as the pandemic drove investors into defensive plays such as biotechs. Additionally,&nbsp;companies that kickstarted COVID-19 vaccine programs ran up sharply in 2020.</p>\n<p>The relatively muted performance so far this year may have to do with the return of risk appetite leading to rotation out of the sector. The rally in vaccine stocks also moderated following emergency use authorizations being accorded for three COVID-19 shots.</p>\n<p>Here are a few stocks that stood out with solid gains amid the muted overall sector performance:</p>\n<p><b>Cassava Sciences&nbsp;Inc</b>&nbsp;: Shares of Cassava, a neurodegenerative disease company, spiked in early February on the back of positive results from the interim analysis of data from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.</p>\n<p>It hit an intraday high of $117.54 on Feb. 4. After pulling back and consolidating, the stock picked up pace in June. By virtue of the strong advance in the year-to-date period, the stock has tacked on about 1,150%.</p>\n<p><b>Annovis Bio&nbsp;Inc</b>&nbsp;: This&nbsp;biopharma&nbsp;that focuses on therapies for neurodegenerative diseases has seen its shares surge by over 1, 060% so far this year.</p>\n<p>The company's lead drug ANVS401 is being evaluated for multiple indications, including Alzheimer's disease and Parkinson's disease. It works by improving axonal transport by inhibiting the neurotoxic proteins that kill nerve cells. A positive Phase 2 readout for the asset in Alzheimer's disease sent the stock soaring in late April.</p>\n<p><b>Atossa Therapeutics&nbsp;Inc</b>&nbsp;: The Seattle-based biopharma focusing on treatments for breast cancer and COVID-19 has surged up about 770% year-to-date.</p>\n<p>From under $1 at the start of year, the stock rallied to a high of $4.90 in early February on the back of positive Phase 2 data for Endoxifen administered between diagnosis and surgery in breast cancer patients. The upward momentum faltered subsequently and the stock pulled back to a low of $1.48 on April 19.</p>\n<p>Atossa recovered from there and the rally picked up steam in June amid the release of positive final Phase 2 data for Endoxifen and inclusion in the Russell 2000&nbsp;and 3000&nbsp;indexes.</p>\n<p><b>Entera Bio Ltd.</b>&nbsp;: The biopharma, which develops orally delivered large molecule therapeutics for use in areas with significant unmet medical need, has seen its shares surge higher by over 460% so far this year.</p>\n<p>The company's pipeline consists of EB613, which is being evaluated for osteoporosis, and EB612 for hypoparathyroidism.</p>\n<p>Entera Bio shares jumped in early April&nbsp;when it reported positive topline biomarker data for EB613. The stock received a shot in the arm from the positive six-month bone mineral density results from the Phase 2 clinical trial of EB613, which the company&nbsp;reportedlast week.</p>\n<p><b>PDS Biotechnology Corp</b>&nbsp;: PDS has gained about 450% year-to-date. The company has oncology and infectious disease programs.</p>\n<p>The gains for the year-to-date period reflected the presentation of data from the Phase 2 combination study with PDS0101 in HPV-associated tumors at the ASCO conference, and also its COVID-19 program.</p>\n<p><b>Anavex Life Sciences Corp.</b>&nbsp;shares have gained about 430% year-to-date. The company is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.</p>\n<p>The company's lead product candidate blarcamesine (ANAVEX2-73) is being evaluated for multiple indications. The predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept Phase 2 trial in Parkinson's disease, the company announced.</p>\n<p><b>Brooklyn ImmunoTherapeutics&nbsp;Inc</b>&nbsp;: This New York-based gene and cell therapy company has clocked gains of about 375% year-to-date.</p>\n<p>The company is focused on exploring the role cytokine-based therapy can have in treating patients with cancer. The company is also exploring opportunities to advance oncology, blood disorder&nbsp;and monogenic disease therapies using highly innovative gene editing/cell therapy technology.</p>\n<p>Brooklyn initiated a mid-stage study of IRX-2 in combination with&nbsp;<b>Merck &amp; Co., Inc.'s</b>&nbsp;Keytruda and chemotherapy in triple-negative breast cancer.</p>\n<p>In March, the company completed its reverse merger with&nbsp;<b>NTN Buzztime</b>.</p>\n<p><b>Howard Federoff</b>&nbsp;took over as CEO in early April. Later that month, the company acquired an exclusive license for mRNA gene editing and cell therapies technology of&nbsp;<b>Factor Bioscience</b>&nbsp;and&nbsp;<b>Novellus Therapeutics</b>, pursuant to an exercise of a previously announced option.</p>\n<p>The company has also been added to the Russell 3000 Index.</p>\n<p>Brooklyn's most advanced program is the study of the lead asset IRX-2, a human cell-derived biologic with multiple active cytokine components&nbsp;in patients with head and neck cancer. With commercialization years away — and ultimately&nbsp;contingent on IRX-2 clearing clinical and regulatory hurdles —&nbsp;the valuation of Brooklyn looks a little stretched.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease, Cancer Stocks Among Top Biotech Gainers In 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-05 13:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ENTX":"Entera Bio Ltd.","ATOS":"Atossa Genetics Inc","MRK":"默沙东","AVXL":"Anavex Life Sciences Corp.","SAVA":"Cassava Sciences Inc","ANVS":"Annovis Bio, Inc.","PDSB":"PDS Biotechnology Corporation"},"source_url":"https://www.benzinga.com/general/biotech/21/07/21773695/neurodegenerative-disease-cancer-stocks-among-top-biotech-gainers-in-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111176344","content_text":"Biotech stocks underperformed the broader market in the first half of 2021, with the iShares Nasdaq Biotechnology ETF advancing about 8% year-to-date compared to the roughly 14% gain for the S&P 500 Index.\nIn comparison, the IBB was up 13.6% in the first half of 2020. The strength in the space in the last year was primarily due to risk aversion as the pandemic drove investors into defensive plays such as biotechs. Additionally, companies that kickstarted COVID-19 vaccine programs ran up sharply in 2020.\nThe relatively muted performance so far this year may have to do with the return of risk appetite leading to rotation out of the sector. The rally in vaccine stocks also moderated following emergency use authorizations being accorded for three COVID-19 shots.\nHere are a few stocks that stood out with solid gains amid the muted overall sector performance:\nCassava Sciences Inc : Shares of Cassava, a neurodegenerative disease company, spiked in early February on the back of positive results from the interim analysis of data from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease.\nIt hit an intraday high of $117.54 on Feb. 4. After pulling back and consolidating, the stock picked up pace in June. By virtue of the strong advance in the year-to-date period, the stock has tacked on about 1,150%.\nAnnovis Bio Inc : This biopharma that focuses on therapies for neurodegenerative diseases has seen its shares surge by over 1, 060% so far this year.\nThe company's lead drug ANVS401 is being evaluated for multiple indications, including Alzheimer's disease and Parkinson's disease. It works by improving axonal transport by inhibiting the neurotoxic proteins that kill nerve cells. A positive Phase 2 readout for the asset in Alzheimer's disease sent the stock soaring in late April.\nAtossa Therapeutics Inc : The Seattle-based biopharma focusing on treatments for breast cancer and COVID-19 has surged up about 770% year-to-date.\nFrom under $1 at the start of year, the stock rallied to a high of $4.90 in early February on the back of positive Phase 2 data for Endoxifen administered between diagnosis and surgery in breast cancer patients. The upward momentum faltered subsequently and the stock pulled back to a low of $1.48 on April 19.\nAtossa recovered from there and the rally picked up steam in June amid the release of positive final Phase 2 data for Endoxifen and inclusion in the Russell 2000 and 3000 indexes.\nEntera Bio Ltd. : The biopharma, which develops orally delivered large molecule therapeutics for use in areas with significant unmet medical need, has seen its shares surge higher by over 460% so far this year.\nThe company's pipeline consists of EB613, which is being evaluated for osteoporosis, and EB612 for hypoparathyroidism.\nEntera Bio shares jumped in early April when it reported positive topline biomarker data for EB613. The stock received a shot in the arm from the positive six-month bone mineral density results from the Phase 2 clinical trial of EB613, which the company reportedlast week.\nPDS Biotechnology Corp : PDS has gained about 450% year-to-date. The company has oncology and infectious disease programs.\nThe gains for the year-to-date period reflected the presentation of data from the Phase 2 combination study with PDS0101 in HPV-associated tumors at the ASCO conference, and also its COVID-19 program.\nAnavex Life Sciences Corp. shares have gained about 430% year-to-date. The company is developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders.\nThe company's lead product candidate blarcamesine (ANAVEX2-73) is being evaluated for multiple indications. The predictive biomarker of response established with SIGMAR1 mRNA expression correlates significantly with responses in primary and secondary clinical efficacy endpoints from the proof-of-concept Phase 2 trial in Parkinson's disease, the company announced.\nBrooklyn ImmunoTherapeutics Inc : This New York-based gene and cell therapy company has clocked gains of about 375% year-to-date.\nThe company is focused on exploring the role cytokine-based therapy can have in treating patients with cancer. The company is also exploring opportunities to advance oncology, blood disorder and monogenic disease therapies using highly innovative gene editing/cell therapy technology.\nBrooklyn initiated a mid-stage study of IRX-2 in combination with Merck & Co., Inc.'s Keytruda and chemotherapy in triple-negative breast cancer.\nIn March, the company completed its reverse merger with NTN Buzztime.\nHoward Federoff took over as CEO in early April. Later that month, the company acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience and Novellus Therapeutics, pursuant to an exercise of a previously announced option.\nThe company has also been added to the Russell 3000 Index.\nBrooklyn's most advanced program is the study of the lead asset IRX-2, a human cell-derived biologic with multiple active cytokine components in patients with head and neck cancer. With commercialization years away — and ultimately contingent on IRX-2 clearing clinical and regulatory hurdles — the valuation of Brooklyn looks a little stretched.","news_type":1},"isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":152366771,"gmtCreate":1625271209393,"gmtModify":1703739627310,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/152366771","repostId":"2148181808","repostType":4,"repost":{"id":"2148181808","kind":"highlight","pubTimestamp":1625237039,"share":"https://ttm.financial/m/news/2148181808?lang=&edition=fundamental","pubTime":"2021-07-02 22:43","market":"us","language":"en","title":"2 Top Growth Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2148181808","media":"Motley Fool","summary":"Amazon.com and CuriosityStream look poised for explosive long-term growth.","content":"<p>Growth stocks are shares in companies that increase revenue and earnings faster than average. And they are an excellent way to earn market-beating returns in the stock market. Let's explore some reasons why&nbsp;<b>Amazon.com</b>&nbsp;(NASDAQ:AMZN) and&nbsp;<b>CuriosityStream</b>&nbsp;(NASDAQ:CURI) have what it takes to supercharge your investment portfolio.&nbsp;</p>\n<h2>1. Amazon</h2>\n<p>With a market cap of $1.74 trillion, Amazon is already <a href=\"https://laohu8.com/S/AONE\">one</a> of the most successful growth stocks of all time, and its bull run is still in full swing. The e-commerce giant trades at a reasonable valuation. It can deliver continued long-term expansion because of strength in its Amazon Prime subscription service and pivots to new markets like healthcare.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F632211%2Fgettyimages-1271085883.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"494\"><span>Image source: Getty Images.</span></p>\n<p>Amazon is working hard to keep its Amazon Prime subscription service ahead of the competition through unique features. The platform currently boasts 200 million subscribers, with an impressive 175 million streaming TV shows and movies in the past year. Streaming is not Prime's primary market (the platform is more geared toward product discounts and faster shipping), but video can boost Amazon's competitive moat against rivals like Walmart+, which offers a similar e-commerce service.&nbsp;&nbsp;</p>\n<p>According to Insider, Amazon is also considering launching brick-and-mortar pharmacies in the U.S. Management hasn't commented on the rumor, but it would be a natural progression from the online delivery pharmacies Amazon launched in November. The U.S. pharmacy and drugstore market is worth $319 billion of annual sales, making it a massive opportunity for Amazon to disrupt.&nbsp;</p>\n<p>First-quarter revenue grew 44%, while operating income surged 122% to $8.9 billion. Amazon's spectacular bottom-line expansion (powered by the high-margin AWS segment ) helps justify its price-to-earnings multiple of 48 times forward estimates.&nbsp;</p>\n<h2>2. CuriosityStream</h2>\n<p>Founded in 2015 and going public in February 2021, CuriosityStream is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the latest start-ups attempting to crack the $50.11 billion video streaming industry. The company's unique market niche, rapid top-line growth rate, and tiny market cap make it an excellent way for investors to bet on this transformational opportunity.&nbsp;</p>\n<p>Unlike rivals such as Disney+ and <b>Netflix</b>, which earn much of their revenue from fictional films and shows, CuriosityStream focuses on non-fictional documentary content. This narrow focus gives the company much-needed differentiation and allows management to unlock synergies with other similar businesses. In May, the company acquired One Day University, an educational content company featuring over 500 talks from professors all over the country. This combination will help strengthen CuriosityStream's moat and expand its content library.&nbsp;</p>\n<p>First-quarter revenue jumped 33% to $9.9 million. Management expects sales to grow 80% to $71 million in full-year 2021. With a market cap of $720 million, the stock trades at just 10 times expected revenue, which looks reasonable considering its rapid growth rate.&nbsp;</p>\n<p>Despite the strong guidance, CuriosityStream has been under pressure after Bank of America downgraded the stock to \"underperform\" after it surpassed the bank's price target at $14 per share (shares have since recovered). The analysts didn't provide any new negative information to justify their downgrade. Anyhow, investors should focus on the long term instead of getting distracted by short-term price fluctuations.&nbsp;</p>\n<h2>Betting on growth</h2>\n<p>Amazon and CuriosityStream both offer outstanding growth in the e-commerce and video streaming industries. Amazon is better for investors who want to bet on a proven business because of its track record of success. CuriosityStream faces more uncertainty, but it offers the potential for multi-bagger returns as its operations expand.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Top Growth Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Top Growth Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-02 22:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/02/2-top-growth-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Growth stocks are shares in companies that increase revenue and earnings faster than average. And they are an excellent way to earn market-beating returns in the stock market. Let's explore some ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/02/2-top-growth-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/02/2-top-growth-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2148181808","content_text":"Growth stocks are shares in companies that increase revenue and earnings faster than average. And they are an excellent way to earn market-beating returns in the stock market. Let's explore some reasons why Amazon.com (NASDAQ:AMZN) and CuriosityStream (NASDAQ:CURI) have what it takes to supercharge your investment portfolio. \n1. Amazon\nWith a market cap of $1.74 trillion, Amazon is already one of the most successful growth stocks of all time, and its bull run is still in full swing. The e-commerce giant trades at a reasonable valuation. It can deliver continued long-term expansion because of strength in its Amazon Prime subscription service and pivots to new markets like healthcare.\nImage source: Getty Images.\nAmazon is working hard to keep its Amazon Prime subscription service ahead of the competition through unique features. The platform currently boasts 200 million subscribers, with an impressive 175 million streaming TV shows and movies in the past year. Streaming is not Prime's primary market (the platform is more geared toward product discounts and faster shipping), but video can boost Amazon's competitive moat against rivals like Walmart+, which offers a similar e-commerce service.  \nAccording to Insider, Amazon is also considering launching brick-and-mortar pharmacies in the U.S. Management hasn't commented on the rumor, but it would be a natural progression from the online delivery pharmacies Amazon launched in November. The U.S. pharmacy and drugstore market is worth $319 billion of annual sales, making it a massive opportunity for Amazon to disrupt. \nFirst-quarter revenue grew 44%, while operating income surged 122% to $8.9 billion. Amazon's spectacular bottom-line expansion (powered by the high-margin AWS segment ) helps justify its price-to-earnings multiple of 48 times forward estimates. \n2. CuriosityStream\nFounded in 2015 and going public in February 2021, CuriosityStream is one of the latest start-ups attempting to crack the $50.11 billion video streaming industry. The company's unique market niche, rapid top-line growth rate, and tiny market cap make it an excellent way for investors to bet on this transformational opportunity. \nUnlike rivals such as Disney+ and Netflix, which earn much of their revenue from fictional films and shows, CuriosityStream focuses on non-fictional documentary content. This narrow focus gives the company much-needed differentiation and allows management to unlock synergies with other similar businesses. In May, the company acquired One Day University, an educational content company featuring over 500 talks from professors all over the country. This combination will help strengthen CuriosityStream's moat and expand its content library. \nFirst-quarter revenue jumped 33% to $9.9 million. Management expects sales to grow 80% to $71 million in full-year 2021. With a market cap of $720 million, the stock trades at just 10 times expected revenue, which looks reasonable considering its rapid growth rate. \nDespite the strong guidance, CuriosityStream has been under pressure after Bank of America downgraded the stock to \"underperform\" after it surpassed the bank's price target at $14 per share (shares have since recovered). The analysts didn't provide any new negative information to justify their downgrade. Anyhow, investors should focus on the long term instead of getting distracted by short-term price fluctuations. \nBetting on growth\nAmazon and CuriosityStream both offer outstanding growth in the e-commerce and video streaming industries. Amazon is better for investors who want to bet on a proven business because of its track record of success. CuriosityStream faces more uncertainty, but it offers the potential for multi-bagger returns as its operations expand.","news_type":1},"isVote":1,"tweetType":1,"viewCount":207,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123501714,"gmtCreate":1624427620738,"gmtModify":1703836372839,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123501714","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://ttm.financial/m/news/1174011543?lang=&edition=fundamental","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p>\n<p>In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p>\n<p>Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p>\n<p>“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p>\n<p>The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p>\n<p>The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p>\n<p>“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p>\n<p>Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p>\n<p>The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p>\n<p>Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p>\n<p>Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p>\n<p>That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p>\n<p>Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p>\n<p>Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p>\n<p>Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p>\n<p>Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p>\n<p>About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p>\n<p>The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p>\n<p>Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p>\n<p>The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p>\n<p>“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p>\n<p>The FDA said it plans to release more documents regarding its decision making as early as next week.</p>\n<p>The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p>\n<p>In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p>\n<p>Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p>\n<p>The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p>\n<p>At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p>\n<p>Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p>\n<p>The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p>\n<p>The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 13:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2><strong>WSJ</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, ...</p>\n\n<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":211,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123506627,"gmtCreate":1624427703869,"gmtModify":1703836375456,"author":{"id":"3582022156707091","authorId":"3582022156707091","name":"GoLUCK","avatar":"https://static.tigerbbs.com/59d744194a62c681a6af1d4f6800825b","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582022156707091","authorIdStr":"3582022156707091"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123506627","repostId":"2145066250","repostType":4,"repost":{"id":"2145066250","kind":"news","pubTimestamp":1624417523,"share":"https://ttm.financial/m/news/2145066250?lang=&edition=fundamental","pubTime":"2021-06-23 11:05","market":"us","language":"en","title":"Goldman Begins Trading on JPMorgan’s Repo Blockchain Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2145066250","media":"Bloomberg","summary":"(Bloomberg) -- Goldman Sachs Group Inc. has joined the blockchain-based network created by JPMorgan ","content":"<p>(Bloomberg) -- Goldman Sachs Group Inc. has joined the blockchain-based network created by JPMorgan Chase &amp; Co. for repurchase agreements that use smart contracts and a digitized version of the U.S. dollar.</p>\n<p>Its first trade came on June 17, when it swapped a tokenized version of a U.S. Treasury bond for JPMCoin, JPMorgan’s internal representation of a digital dollar, according to Mathew McDermott, global head of digital assets for Goldman’s global markets division. He declined to give the value of the trade.</p>\n<p>“We see this as a pivotal moment for the digitization of transactional activity,” McDermott said Tuesday in an interview. Unlike in the traditional repo market, the exact amount of time the banks took to complete the transaction was quantifiable. In this case, it was 3 hours and 5 minutes.</p>\n<p>Knowing the precise time is a big step up from the current market, as is the way the collateral and cash are interchanged simultaneously and immediately, McDermott said.</p>\n<p>“We pay interest per the minute,” he said. “We firmly think this will change the nature of the intraday marketplace.”</p>\n<p>Read more: JPMorgan Using Blockchain to Move Billions in Repo-Market Trades</p>\n<p>JPMorgan created the new repo market using its version of the Ethereum blockchain, with its first trades in December. It has since gone on to trade more than $1 billion a day through its Onyx blockchain platform. The firm is speaking with more than 10 banking and investing clients about joining the repo network, according to spokeswoman Jessica Francisco. Bank of New York Mellon Corp. served as the custody agent for the trades.</p>\n<p>Transactions in the $2.4 trillion repo market raise cash overnight or for a few days, but are difficult to arrange within the same trading day. The digitized upgrade provides that ability to JPMorgan, using so-called smart contracts on an Ethereum-based blockchain that allow cash and Treasuries to be returned instantaneously.</p>\n<p>Wall Street began experimenting with blockchain about five years ago. In addition to JPMorgan, a blockchain pioneer among Wall Street banks, Paxos Trust Co. is using it to settle some equity trades in near-real time. Arca is offering digital shares in a U.S. Treasury fund, showing that distributed-ledger technology can help streamline finance.</p>\n<p>McDermott said Goldman Sachs’s participation in the JPMorgan market fits in broadly with how it’s thinking about enterprise blockchain, a system where all participants are known to <a href=\"https://laohu8.com/S/AONE\">one</a> another.</p>\n<p>“There’s the growing focus on the potential of this technology,” he said. Then he added something rarely heard from rival bankers:</p>\n<p>“It’s been great working with JPMorgan and BNY on this.”</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Begins Trading on JPMorgan’s Repo Blockchain Network</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Begins Trading on JPMorgan’s Repo Blockchain Network\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-23 11:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/goldman-begins-trading-jpmorgan-repo-204523872.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Goldman Sachs Group Inc. has joined the blockchain-based network created by JPMorgan Chase & Co. for repurchase agreements that use smart contracts and a digitized version of the U.S. ...</p>\n\n<a href=\"https://finance.yahoo.com/news/goldman-begins-trading-jpmorgan-repo-204523872.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","JPM":"摩根大通"},"source_url":"https://finance.yahoo.com/news/goldman-begins-trading-jpmorgan-repo-204523872.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2145066250","content_text":"(Bloomberg) -- Goldman Sachs Group Inc. has joined the blockchain-based network created by JPMorgan Chase & Co. for repurchase agreements that use smart contracts and a digitized version of the U.S. dollar.\nIts first trade came on June 17, when it swapped a tokenized version of a U.S. Treasury bond for JPMCoin, JPMorgan’s internal representation of a digital dollar, according to Mathew McDermott, global head of digital assets for Goldman’s global markets division. He declined to give the value of the trade.\n“We see this as a pivotal moment for the digitization of transactional activity,” McDermott said Tuesday in an interview. Unlike in the traditional repo market, the exact amount of time the banks took to complete the transaction was quantifiable. In this case, it was 3 hours and 5 minutes.\nKnowing the precise time is a big step up from the current market, as is the way the collateral and cash are interchanged simultaneously and immediately, McDermott said.\n“We pay interest per the minute,” he said. “We firmly think this will change the nature of the intraday marketplace.”\nRead more: JPMorgan Using Blockchain to Move Billions in Repo-Market Trades\nJPMorgan created the new repo market using its version of the Ethereum blockchain, with its first trades in December. It has since gone on to trade more than $1 billion a day through its Onyx blockchain platform. The firm is speaking with more than 10 banking and investing clients about joining the repo network, according to spokeswoman Jessica Francisco. Bank of New York Mellon Corp. served as the custody agent for the trades.\nTransactions in the $2.4 trillion repo market raise cash overnight or for a few days, but are difficult to arrange within the same trading day. The digitized upgrade provides that ability to JPMorgan, using so-called smart contracts on an Ethereum-based blockchain that allow cash and Treasuries to be returned instantaneously.\nWall Street began experimenting with blockchain about five years ago. In addition to JPMorgan, a blockchain pioneer among Wall Street banks, Paxos Trust Co. is using it to settle some equity trades in near-real time. Arca is offering digital shares in a U.S. Treasury fund, showing that distributed-ledger technology can help streamline finance.\nMcDermott said Goldman Sachs’s participation in the JPMorgan market fits in broadly with how it’s thinking about enterprise blockchain, a system where all participants are known to one another.\n“There’s the growing focus on the potential of this technology,” he said. Then he added something rarely heard from rival bankers:\n“It’s been great working with JPMorgan and BNY on this.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}